NovaBay Pharmaceuticals Inc (NBY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NovaBay Pharmaceuticals Inc (NBY) has a cash flow conversion efficiency ratio of 0.100x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.27 Million) by net assets ($-22.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NovaBay Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how NovaBay Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read NovaBay Pharmaceuticals Inc total liabilities for a breakdown of total debt and financial obligations.
NovaBay Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NovaBay Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stablecoin Development Corporation
NYSE MKT:SDEV
|
0.100x |
|
Dancomech Holdings Bhd
KLSE:5276
|
0.019x |
|
German High Street Properties A/S Class B
CO:GERHSP
|
0.009x |
|
GBK Beteiligungen AG
HM:GBQ
|
N/A |
|
EITA Resources Bhd
KLSE:5208
|
0.038x |
|
Far East Fame Line DDB Public Company Limited
BK:FE
|
0.005x |
|
Career Point Limited
NSE:CAREERP
|
0.004x |
|
Chi Hua Fitness Co Ltd
TWO:1593
|
0.029x |
Annual Cash Flow Conversion Efficiency for NovaBay Pharmaceuticals Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of NovaBay Pharmaceuticals Inc from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of NovaBay Pharmaceuticals Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-22.83 Million | $-8.43 Million | 0.369x | -99.08% |
| 2024-12-31 | $-129.00K | $-5.18 Million | 40.178x | +3224.87% |
| 2023-12-31 | $3.31 Million | $-4.26 Million | -1.286x | -103.94% |
| 2022-12-31 | $10.55 Million | $-6.65 Million | -0.630x | +30.24% |
| 2021-12-31 | $10.17 Million | $-9.19 Million | -0.904x | -135.80% |
| 2020-12-31 | $12.32 Million | $-4.72 Million | -0.383x | +95.30% |
| 2019-12-31 | $973.00K | $-7.93 Million | -8.149x | -625.04% |
| 2018-12-31 | $4.95 Million | $-5.57 Million | -1.124x | +53.50% |
| 2017-12-31 | $2.59 Million | $-6.27 Million | -2.417x | -41.44% |
| 2016-12-31 | $7.10 Million | $-12.13 Million | -1.709x | -146.94% |
| 2015-12-31 | $-5.10 Million | $-18.56 Million | 3.640x | +144.69% |
| 2014-12-31 | $1.85 Million | $-15.05 Million | -8.147x | -434.94% |
| 2013-12-31 | $8.52 Million | $-12.97 Million | -1.523x | -227.75% |
| 2012-12-31 | $14.05 Million | $-6.53 Million | -0.465x | -38.19% |
| 2011-12-31 | $9.34 Million | $-3.14 Million | -0.336x | -273.93% |
| 2010-12-31 | $10.49 Million | $2.03 Million | 0.193x | +256.55% |
| 2009-12-31 | $13.35 Million | $-1.65 Million | -0.123x | +90.88% |
| 2008-12-31 | $7.34 Million | $-9.94 Million | -1.354x | -209.09% |
| 2007-12-31 | $14.32 Million | $-6.27 Million | -0.438x | -116.74% |
| 2006-12-31 | $1.81 Million | $4.74 Million | 2.617x | +363.45% |
| 2005-12-31 | $3.25 Million | $-3.23 Million | -0.993x | -- |
About NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals, Inc. engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol. Its services intend to support protocol-level services, including staking, governance participation, validation, and related activities. T… Read more